SEC Form 4 · accession 0001209191-18-004909
Ovid Therapeutics Inc. · OVID
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dirk Haasner
Officer — SVP, Global Regulatory Affairs
Period of report
Jan 19, 2018
Accepted (ET)
Jan 23, 2018 · 4:40 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001636651
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $9.18 | Jan 19, 2018 | A | 30,000 | A | — | Jan 18, 2028 | Common Stock | 30,000 | 30,000 | D |
Explanation of responses
- F125% of the shares subject to the Stock Option will vest and become exercisable on January 19, 2019 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued service through each such date.